美国复发难治大B细胞淋巴瘤CAR-T转诊模式与利用分析
转诊患者更年轻且距中心更近,二线队列中CAR-T组至下一治疗或死亡时间更长。
要点
- 多数符合条件患者未接受CAR-T,主要因转诊缺口或中心选择替代治疗。
- 转诊患者中位年龄61.5岁、距中心17英里,未转诊者67.3岁、24英里。
- 二线队列CAR-T组至下一治疗或死亡中位28个月,非治疗组12个月。
核心结论
- 多数符合条件的复发难治大B细胞淋巴瘤患者未接受CAR-T治疗,转诊缺口或授权治疗中心替代治疗选择是主要原因。
- 加强转诊路径并提高对CAR-T获益的认识可能促进更广泛、更公平的可及性。
研究设计与样本
- 纳入≥2线治疗后接受CAR-T治疗于授权治疗中心的成人复发难治大B细胞淋巴瘤患者,共8959例,按转诊与治疗状态分层。
主要发现
- 8959例中20%转诊至授权治疗中心,15%接受CAR-T治疗(7%源于授权治疗中心,8%转诊至授权治疗中心)。
- 转诊患者更年轻(中位年龄61.5 vs 67.3岁;P<0.001)且距授权治疗中心更近(中位距离17 vs 24英里;P<0.001)。
- 转诊患者中,接受与未接受CAR-T治疗组的基线人口学特征相似。
- 二线封闭理赔队列中,CAR-T受者至下一治疗或死亡时间较非治疗组更长(中位28 vs 12个月;P<0.005)。
- 输注后1个月住院利用达峰(平均1.54 vs 0.62次就诊),随后降至相近水平(0.81 vs 0.59)。
临床怎么用
- 对复发难治大B细胞淋巴瘤患者应及早评估并强化向授权治疗中心的转诊路径。
- 提高临床医生对CAR-T治疗获益的认识,以减少符合条件患者未转诊或未治疗的情况。
局限性
- 基于美国理赔数据的回顾性分析,可能存在编码与选择偏倚。
- 研究结果来自摘要,未报告完整的方法学细节与混杂因素控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with relapsed/refractory (R/R) large B‑cell lymphoma (LBCL), yet access in routine clinical practice remains limited. We evaluated referral patterns, durability of clinical benefit, and health care resource utilization (HCRU) among US patients with R/R LBCL. Komodo Health US claims data were retrospectively analyzed (October 2016‒May 2025). Adults with R/R LBCL after ≥2 prior lines of therapy who received CAR T-cell therapy at authorized treatment centers (ATC) were included; patients were stratified by referral and treatment status. Outcomes included referral rates, demographics and subsequent treatment, time‑to‑next treatment or death (TTNT-D), and 12‑month postinfusion HCRU. Among 8959 patients, 20% were referred to an ATC and 15% received CAR T-cell therapy (7% originated at an ATC, 8% referred to an ATC). Referred patients were younger (median age, 61.5 vs 67.3 years; P<0.001) and lived closer to ATCs (median distance 17 vs 24 miles; P<0.001). Among referred patients, baseline demographics were similar between CAR T-cell therapy-treated and nontreated groups. In the second‑line closed‑claims cohort, CAR T-cell therapy recipients had longer TTNT-D compared with the nontreated group (median 28 vs 12 months; P<0.005). Inpatient utilization peaked at 1 month postinfusion (mean 1.54 vs 0.62 visits) before declining to similar rates (0.81 vs 0.59). Most eligible patients with R/R LBCL did not receive CAR T-cell therapy due to referral gaps or alternative treatment selection at ATCs. Strengthening referral pathways and increasing awareness of the benefits of CAR T-cell therapy may enable broader, more equitable access.
引用
- Shadman, Nastoupil, Patel, et al. CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States. Blood Adv. 2026. PMID: 42950247. doi:10.1182/bloodadvances.2026021289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。